TC BioPharm Announces Grant Funding In Collaboration With Queen Mary University Of London
Portfolio Pulse from Happy Mohamed
TC BioPharm (NASDAQ:TCBP), a clinical stage biotechnology company, has entered into a collaboration agreement with Queen Mary University of London (QMUL) to research the therapeutic potential of gamma-delta T cells for the treatment of mucosal infections. The collaboration has received grant funding from The Impact Fund arm of QMUL. The project aims to understand how gamma delta T-cell function becomes dysregulated in infectious and inflammatory diseases and could potentially be restored by novel immunotherapies.
September 05, 2023 | 12:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TC BioPharm's collaboration with QMUL and the grant funding received could potentially boost the company's research and development efforts in gamma-delta T cell therapies. This could lead to the development of novel immunotherapies, potentially enhancing the company's product portfolio and future revenue prospects.
The collaboration with QMUL and the grant funding received will likely enhance TC BioPharm's research capabilities in gamma-delta T cell therapies. This could lead to the development of novel immunotherapies, potentially expanding the company's product portfolio and enhancing its future revenue prospects. Therefore, the news is likely to have a positive impact on TCBP's stock in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100